Sponsor or institution
Clinical trials and research at FindCure Biosciences (ZhongShan) Co., Ltd.
As of November 12, 2026, Find a Trial lists 4 clinical trials run by FindCure Biosciences (ZhongShan) Co., Ltd. that are recruiting, in China. By phase: Early Phase 1 (3), Phase 1/2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Lu-177 FC516 safety and dosimetry in metastatic castration-resistant prostate cancer | Early Phase 1 | Wuxi, Jiangsu | Recruiting | Apr 21, 2026 |
| Dosimetry, Safety and Diagnostic Testing of 68Ga-FC516 in Healthy Adults and Men with Prostate Cancer | Early Phase 1 | Guangzhou, Guangdong | Recruiting | Mar 12, 2026 |
| Safety and dosing of 177Lu-INN805 in patients with malignant solid tumors | Early Phase 1 | Wuxi, Jiangsu | Recruiting | Mar 9, 2026 |
| FC084CSA combined with tislelizumab for advanced solid tumors | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | Jul 12, 2024 |
All recruiting trials (4)
-
Lu-177 FC516 safety and dosimetry in metastatic castration-resistant prostate cancer
This study tests whether a Lu-177 labeled therapy (FC516) is safe and shows promising activity in adults with metastatic castration-resistant prostate cancer who have already tried standard treatments.
-
Dosimetry, Safety and Diagnostic Testing of 68Ga-FC516 in Healthy Adults and Men with Prostate Cancer
This trial will test whether a new PET tracer called 68Ga-FC516 is safe and produces clear diagnostic images in healthy adults and men with prostate cancer.
-
Safety and dosing of 177Lu-INN805 in patients with malignant solid tumors
This early-phase, single-arm study tests different dose levels of 177Lu-INN805 to see if it can be safely given and if it shows signs of activity in adults with hard-to-treat solid tumors.
-
FC084CSA combined with tislelizumab for advanced solid tumors
This trial tests whether adding the experimental drug FC084CSA to the immunotherapy tislelizumab helps adults (18–75) with advanced solid tumors that have progressed after standard treatments.
Quick answers
How many clinical trials run by FindCure Biosciences (ZhongShan) Co., Ltd. are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Early Phase 1: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.